Researcher

Arvid Carlsson

Profile

Arvid Carlsson was a Swedish pharmacologist at the University of Gothenburg who shared the 2000 Nobel Prize in Physiology or Medicine with Paul Greengard and Eric Kandel for contributions to signal transduction in the nervous system. Carlsson's most influential discovery was that dopamine is an independent neurotransmitter in the brain—not merely a precursor to norepinephrine—and that its depletion causes the motor symptoms of Parkinson's disease. This discovery directly led to the development of L-DOPA as the primary treatment for Parkinson's disease, one of the most consequential examples of bench-to-bedside translation in neuropharmacology. Carlsson also developed the first selective serotonin reuptake inhibitor (SSRI) concept and contributed to zimelidine, paving the way for fluoxetine (Prozac) and the entire SSRI class of antidepressants. His work fundamentally established monoamine neurotransmission as the pharmacological basis for treating psychiatric and neurological diseases. The legacy of Carlsson's research encompasses the entire neurotransmitter-targeted drug sector, including treatments for Parkinson's, depression, schizophrenia, and ADHD, representing hundreds of billions in pharmaceutical market value.

Industry Ties